JP2019520342A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520342A5 JP2019520342A5 JP2018563040A JP2018563040A JP2019520342A5 JP 2019520342 A5 JP2019520342 A5 JP 2019520342A5 JP 2018563040 A JP2018563040 A JP 2018563040A JP 2018563040 A JP2018563040 A JP 2018563040A JP 2019520342 A5 JP2019520342 A5 JP 2019520342A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- conjugate
- ring
- present
- binding site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 19
- 102000004877 Insulin Human genes 0.000 claims description 10
- 108090001061 Insulin Proteins 0.000 claims description 10
- 229940125396 insulin Drugs 0.000 claims description 10
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 3
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000003248 secreting effect Effects 0.000 claims description 3
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 2
- 108010019598 Liraglutide Proteins 0.000 claims description 2
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical group C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims description 2
- 229960002701 liraglutide Drugs 0.000 claims description 2
- 108010004367 lixisenatide Proteins 0.000 claims description 2
- 229960001093 lixisenatide Drugs 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims 12
- 150000003214 pyranose derivatives Chemical group 0.000 claims 12
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- -1 or I Inorganic materials 0.000 claims 6
- 125000004193 piperazinyl group Chemical group 0.000 claims 5
- 101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims 3
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 108091052347 Glucose transporter family Proteins 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- FRJOXJBNQDZEBI-ZLUOBGJFSA-N (2r,3s,5s)-2,3,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)C[C@H](O)[C@@H](O)C=O FRJOXJBNQDZEBI-ZLUOBGJFSA-N 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 150000002243 furanoses Chemical group 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- ZMAKHBFMBBEKBJ-JJYYJPOSSA-N (2r,3s,4s)-2-(hydroxymethyl)-3,4-dihydro-2h-pyran-3,4,5,6-tetrol Chemical class OC[C@H]1OC(O)=C(O)[C@@H](O)[C@@H]1O ZMAKHBFMBBEKBJ-JJYYJPOSSA-N 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 150000002016 disaccharides Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 150000002231 fructose derivatives Chemical class 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 150000002402 hexoses Chemical class 0.000 claims 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 150000002972 pentoses Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305640.1 | 2016-06-02 | ||
| EP16305640 | 2016-06-02 | ||
| PCT/EP2017/063447 WO2017207754A1 (en) | 2016-06-02 | 2017-06-02 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019520342A JP2019520342A (ja) | 2019-07-18 |
| JP2019520342A5 true JP2019520342A5 (cg-RX-API-DMAC7.html) | 2021-09-24 |
Family
ID=56121007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563040A Ceased JP2019520342A (ja) | 2016-06-02 | 2017-06-02 | グルコース感知タンパク質に結合することができる薬剤および部分のコンジュゲート |
Country Status (13)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018014929A (es) * | 2016-06-02 | 2019-08-26 | Sanofi Sa | Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa. |
| CN111433193A (zh) | 2017-12-01 | 2020-07-17 | 赛诺菲 | 药剂和能够结合至葡萄糖传感蛋白的部分的新型缀合物 |
| KR20230153387A (ko) | 2021-02-02 | 2023-11-06 | 리미널 바이오사이언시스 리미티드 | Gpr84 길항제 및 이의 용도 |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Gpr84アンタゴニストおよびその使用 |
| CN115920081B (zh) * | 2022-11-02 | 2024-07-19 | 重庆大学 | 红细胞膜自发定向包被ros响应的纳米前药及其应用 |
| WO2025199666A1 (en) * | 2024-03-25 | 2025-10-02 | Canwell Biotech Limited | Multivalent linkers for high loading antibody-drug conjugates, and compositions and methods thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK111489D0 (da) | 1989-03-08 | 1989-03-08 | Novo Nordisk As | Peptider |
| AU2001263775A1 (en) | 2000-06-02 | 2001-12-11 | Novo-Nordisk A/S | Glucose dependent release of insulin from glucose sensing insulin derivatives |
| EP1453860A2 (en) | 2001-12-02 | 2004-09-08 | Novo Nordisk A/S | Novel glucose-dependant insulins |
| JP2011506442A (ja) * | 2007-12-11 | 2011-03-03 | コンジュケム バイオテクノロジーズ インコーポレイテッド | インスリン分泌性ペプチド結合体の製剤 |
| FR2929615B1 (fr) | 2008-04-02 | 2010-12-17 | Tfchem | Composes c-aryl glycosides pour le traitement du diabete et de l'obesite. |
| CN101638423B (zh) | 2008-07-29 | 2012-09-05 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 根皮苷衍生物及其制备方法和用途 |
| AU2009294606A1 (en) | 2008-09-19 | 2010-03-25 | Novartis Ag | Glycoside derivatives and uses thereof |
| RU2011135730A (ru) | 2009-01-28 | 2013-03-10 | Смартселлз, Инк. | Кристаллические инсулин-коньюгаты |
| WO2010088294A1 (en) | 2009-01-28 | 2010-08-05 | Smartcells, Inc. | Conjugate based systems for controlled drug delivery |
| WO2010107520A1 (en) | 2009-03-20 | 2010-09-23 | Smartcells, Inc. | Soluble non-depot insulin conjugates and uses thereof |
| EP2448962B1 (en) | 2009-06-30 | 2016-10-19 | Novo Nordisk A/S | Insulin derivatives |
| EP2549863A4 (en) * | 2010-03-24 | 2014-01-01 | Univ Ohio | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORTATION |
| WO2012015681A2 (en) | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Drug-ligand conjugates, synthesis thereof, and intermediates thereto |
| JP2013535467A (ja) | 2010-07-28 | 2013-09-12 | スマートセルズ・インコーポレイテツド | 組換えにより発現されたインスリンポリペプチドおよびその使用 |
| JP2014510782A (ja) | 2011-04-14 | 2014-05-01 | ノバルティス アーゲー | グリコシド誘導体およびその使用 |
| WO2012177701A2 (en) | 2011-06-20 | 2012-12-27 | Radiomedix Inc. | Compositions, methods of synthesis and use of carbohydrate targeted agents |
| CA2864432A1 (en) | 2012-02-15 | 2013-08-22 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| US20150086521A1 (en) | 2012-03-21 | 2015-03-26 | Erytech Pharma | Medicament for the Treatment of Acute Myeloid Leukemia (AML) |
| WO2013182612A1 (en) * | 2012-06-07 | 2013-12-12 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| EP2813234A1 (en) | 2013-06-11 | 2014-12-17 | Erytech Pharma | Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof |
| US9884125B2 (en) | 2013-10-04 | 2018-02-06 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
| LT3094731T (lt) | 2014-01-15 | 2019-10-25 | Baseclick Gmbh | Sacharidais modifikuotos nukleorūgšties molekulės |
| FR3017299B1 (fr) | 2014-02-12 | 2018-05-18 | Erytech Pharma | Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur |
| CN108778318B (zh) * | 2016-01-14 | 2022-05-03 | 北卡罗莱纳州立大学 | 葡萄糖响应性胰岛素递送组合物和方法 |
| MX2018014929A (es) | 2016-06-02 | 2019-08-26 | Sanofi Sa | Conjugados de un agente farmaceutico y una porcion capaz de unirse a una proteina sensora de glucosa. |
-
2017
- 2017-06-02 MX MX2018014929A patent/MX2018014929A/es unknown
- 2017-06-02 CN CN201780047924.9A patent/CN109562185A/zh active Pending
- 2017-06-02 RU RU2018147235A patent/RU2018147235A/ru not_active Application Discontinuation
- 2017-06-02 BR BR112018074716-5A patent/BR112018074716A2/pt not_active Application Discontinuation
- 2017-06-02 SG SG11201810701XA patent/SG11201810701XA/en unknown
- 2017-06-02 JP JP2018563040A patent/JP2019520342A/ja not_active Ceased
- 2017-06-02 AU AU2017272862A patent/AU2017272862A1/en not_active Abandoned
- 2017-06-02 WO PCT/EP2017/063447 patent/WO2017207754A1/en not_active Ceased
- 2017-06-02 EP EP17730714.7A patent/EP3463480A1/en not_active Withdrawn
- 2017-06-02 KR KR1020187038181A patent/KR20190015413A/ko not_active Ceased
- 2017-06-02 US US16/306,243 patent/US11090364B2/en active Active
- 2017-06-02 CA CA3025988A patent/CA3025988A1/en not_active Abandoned
-
2018
- 2018-11-29 IL IL263390A patent/IL263390A/en unknown
-
2021
- 2021-06-23 US US17/356,339 patent/US20210401947A1/en not_active Abandoned
- 2021-06-23 US US17/356,294 patent/US20210401946A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kuijpers et al. | Expedient synthesis of triazole-linked glycosyl amino acids and peptides | |
| RU2018147235A (ru) | Конъюгаты фармацевтического средства и фрагмента, способного связываться с глюкозочувствительным белком | |
| EP1198254B1 (de) | Träger-pharmaka-konjugate | |
| RU2190594C2 (ru) | Органические нитраты и фармацевтическая композиция, обладающая ингибирующей агрегацию тромбоцитов активностью, на их основе | |
| JP4392065B2 (ja) | 腫瘍および炎症性疾患治療用の新規プロドラッグ | |
| KR950702829A (ko) | 신경계 퇴행성 질환의 치료에 유용한 아나바세인 유도체 | |
| JP2010502582A5 (cg-RX-API-DMAC7.html) | ||
| SG173117A1 (en) | Crystalline insulin-conjugates | |
| ATE205725T1 (de) | Polymergebundene paclitaxel-derivate | |
| US20210252160A1 (en) | Compounds, compositions, methods, and uses for treating cancer and immunological disorders | |
| IE890810L (en) | Pharmaceutical formulations for parenteral use | |
| RU2005137360A (ru) | Органические соединения | |
| JP2019511497A5 (cg-RX-API-DMAC7.html) | ||
| RU2002100058A (ru) | Кристаллические производные 1-метилкарбапенема | |
| DE10310082A1 (de) | Protein-bindende Doxorubicin-Peptid-Derivate | |
| WO2002028345A2 (en) | Aldehyde-releasing compounds | |
| US11541122B2 (en) | Glucose sensitive insulins and uses thereof | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| CN102391323B (zh) | 四氢-β-咔啉衍生物、其制备方法及其用途 | |
| CA2411172C (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors | |
| RU2005105066A (ru) | Новые гем-дифторированные соединения, способы их получения и их применение | |
| Kapoor et al. | Bio-active conjugates of curcumin having ester, peptide, thiol and disulfide links | |
| US20070259889A1 (en) | Protein Binding Compounds | |
| RU2010137336A (ru) | Производное 3,8-диаминотетрагидрохинолина | |
| JP2003212893A (ja) | アミド結合型糖鎖含有カルボシランデンドリマーおよびその製造方法 |